China Pharma

CIK 0001106644 · CPHI NYSE American

SIC
2834 · Pharmaceutical Preparations
Type
Operating
Status
Public
Filer
Non-accelerated filer and smaller reporting company
Incorporated
Delaware
FY End
Dec 31

Business Summary

China Pharma Holdings, Inc. is a Nevada-incorporated holding company that operates entirely through its wholly owned PRC subsidiary, Hainan Helpson Medical and Biotechnology Co., Ltd. ("Helpson"), based in Haikou, Hainan Province. Through Helpson, the company develops, manufactures, and markets pharmaceutical products for human use in the PRC, primarily targeting high-incidence and high-mortality diseases including cardiovascular, CNS, infectious, and digestive conditions. Revenue is generated through product sales of NMPA-approved prescription drugs distributed via provincially licensed pharmaceutical logistics companies to hospitals and OTC pharmacies.

Products & Services

Pharmaceutical Products (19 approved, prescription-based):

  • CNS & Cerebrovascular (7 products): Cerebroprotein Hydrolysate Injection, Gastrodin Injection, Propylgallate for Injection, Ozagrel Sodium for Injection, Alginic Sodium Diester Injection, Bumetanide for Injection, Candesartan (hypertension; passed consistency evaluation August 2023)
  • Anti-Infection & Respiratory (6 products): Roxithromycin Dispersible Tablets, Cefaclor Dispersible Tablets, Cefalexin Capsules, Andrographolide, Clarithromycin Granules and Capsules, Naproxen Sodium/Pseudophedrine Sustained Release Tablet...
Get a free account in seconds to read the full business overview. Create free account

AI-generated summary of Item 1 (Business) from the 10-K filed Mar 31, 2025 — View filing on SEC.gov. May contain errors — refer to the filing for authoritative information.

Across SEC filings

Institutional holders · 13F

Q3 2026
7 managers reported a position for Q3 2026 Unchanged vs Q2 2026
Largest Q3 2026 Form 13F holders of China Pharma by reported value
Largest holders Reported value
SABBY MANAGEMENT LLC $202.6K
JANE STREET GROUP LLC $23.3K
Virtu Financial LLC $16.0K
StoneX Group Inc $13.6K
XTX Topco Ltd $8.2K

Annual results · 10-K

Fiscal 2025
Revenue
$4.1M
Net loss
-$3.2M

As reported in the fiscal 2025 annual report.

Securities

Securities issued by this company
CUSIP Security Type
16941T401 CPHI CHINA PHARMA HOLDINGS INC Common stock

Latest SEC filings

All filings →
Latest SEC filings by China Pharma
Form Description Filed
10-Q QUARTERLY REPORT 2026-11-18
NT 10-Q NOTIFICATION OF LATE FILING 2026-11-17
DEF 14A DEFINITIVE PROXY STATEMENT 2026-11-10
PRE 14A PRELIMINARY PROXY STATEMENT 2026-10-30
10-Q QUARTERLY REPORT 2026-08-14
424B5 PROSPECTUS SUPPLEMENT 2026-07-23
8-K CURRENT REPORT 2026-07-22
10-Q QUARTERLY REPORT 2026-05-15
10-K ANNUAL REPORT 2026-04-01
NT 10-K NOTIFICATION OF LATE FILING 2026-04-01
Loading ownership data...
Loading insider trading data...
Loading financials...

Quality is a Plus feature

See why the score is what it is — the score history and the full test-by-test breakdown behind the composite.

Valuation is a Premium feature

What this company is worth versus its price — fair value at today's bond rate, margin of safety, and the Graham Number against the institutional consensus price.

Loading SEC filings...